German industry keeps close eye on undue pressure on suppliers:
This article was originally published in Clinica
Customers seeking discounts from suppliers - in whatever industry sector - is common business practice. German medtech industry association Spectaris notes, however, that pressure from clinics on suppliers to alter price schedules to suit a single - albeit economically important - customer (or group of customers acting as a cartel) effectively contravenes the law on unfair competition (UWG). This is the case if the supplier is constrained by the action of a hospital or clinic in such a way as to prevent it from acting freely. In the era of diagnosis-related groups (DRGs) and tighter budgets, resulting from past and ongoing health finance reforms, the issue is one that industry needs to keep an eye on, feels Spectaris. The association's Harald Hartmann (email@example.com) is currently assessing the extent of the problem.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.